Cell therapy products are revolutionizing multiple therapeutic areas; to maintain this pace of innovation, manufacturing solutions must adapt

Although cell therapies continue to reshape multiple therapeutics areas, the field is still grappling with how to best manufacture therapies. Allogeneic therapies are currently manufactured at a larger scale, but additional effort is required to optimize starting material choice, final product shipping logistics, and whether incremental patient-specific cell modification is needed at the point-of-care. Autologous cell therapies are currently manufactured at a commercial scale but for smaller patient populations. This will change. As autologous cell therapy manufacturing expands, manufacturing platforms, which are closed, automated, and scalable, will be vital. The migration to closed, automated, and scalable manufacturing platforms will provide an avenue to decrease therapeutic cost while maintaining quality and increasing patient access. This is critical for the field's continued evolution.